A5063929724- Lipoproteins and Cardiovascular Health
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Coenzyme Q10 studies and effects
- Renin-Angiotensin System Studies
- Pulmonary Hypertension Research and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Infective Endocarditis Diagnosis and Management
- Adipokines, Inflammation, and Metabolic Diseases
- Blood properties and coagulation
- Atrial Fibrillation Management and Outcomes
- Neurological Disorders and Treatments
- Cardiovascular Disease and Adiposity
- Coronary Interventions and Diagnostics
- Clinical Laboratory Practices and Quality Control
- Global Health and Surgery
- Advanced Causal Inference Techniques
- Medication Adherence and Compliance
- Cardiovascular Health and Risk Factors
- Cancer Research and Treatment
Mayo Clinic in Florida
2024-2025
WinnMed
2024-2025
Zagazig University
2016-2024
Mayo Clinic in Arizona
2024
Mayo Clinic Hospital
2024
Gadarif University
2018-2024
World Health Organization - Egypt
2023
Sudan International University
2017
Scientific Research Group in Egypt
2016-2017
Abstract Aims Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim this study to investigate between Lp(a) ISR. Methods results A retrospective adult patients who underwent successful PCI January 2006 December 2017 at three Mayo Clinic sites had a preprocedural measurement was conducted. Patients...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although lipoprotein(a) [Lp(a)] known to be a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD), its role in development of AF, independent this association, remains unclear. Adult patients from three Mayo Clinic sites with baseline Lp(a) and without AF history were included. Patients categorized into two groups based on their levels: high (≥50 mg/dL) low (<50 mg/dL). Survival probabilities free...
Lipoprotein(a) [Lp(a)] levels are known to be mainly genetically determined. However, only scarce data available on the intra-individual variability of Lp(a) across time.